world-biotechnology-2017-scientifictracks-abstracts

5 / 39

conferenceseries .com
Page 30
Notes:
Volume 7, Issue 6 (Suppl) J Biotechnol Biomater, an open access journal
ISSN: 2155-952X World Biotechnology 2017
December 04-05, 2017
2nd World Biotechnology Congress
December 04-05, 2017 | Sao Paulo, Brazil
Scaling up the biotechnological process of the recombinant rabies virus glycoprotein
Monize C Decarli1, Diogo P dos Santos1, Renato Astray2, Daniella C Ventini-Monteiro2, Soraia A C Jorge2, Daniela M Correia1, Juliana S da Silva1, Mayra P
Rocca3, Hélio Langoni3, Benedito D Menozzi3, Carlos A Pereira2 and Claudio A T Suazo1
1Federal University of São Carlos, Brazil
2Butantan Institute, Brazil
3São Paulo State University, Brazil
The rabies virus glycoprotein (RVGP) is the main antigen of vaccine formulations. A robust Drosophila S2 cell line (S2MtRVGPH-
His) was engineered by our group for the expression of recombinant RVGP (rRVGP) using metal-inducible promoters. The
objective of this work was to evaluate the potential of a WAVE BioreactorTM in the initial steps of scaling-up the rRVGP production
process by the S2MtRVGPH-His cell line to produce rRVGP in sufficient quantities for immunization and characterization studies.
The WAVE bioreactor is an innovative approach for the cultivation of animal cells as it offers high process flexibility, as well as cost
and time savings. For this purpose, we firstly established a Schott flasks procedure for culturing the S2MtRVGPH-His lineage. Using
an inoculum of 5x105 cells/mL in culture medium (Sf900-III) induced with CuSO4, adequate pH range and parameter values such
as time of induction (72 h) and temperature (28°C) to optimize rRVGP production could be defined. In the sequence, the procedure
was reproduced in culture experiments conducted in a WAVE bioreactor 2/10 using a 2 L Cellbag. The results in Schott flasks and
WAVE bioreactor were very similar, yielding a maximum titer of rRVGP above of 1 mg/L. After the rRVGP production process, the
animals were immunized with rRVGP and submitted to rabies virus challenge. The rRVGP assessed in the immune system of the
vaccinated animals showed high levels of anti-RVGP antibodies, statistically not different from the levels induced by a commercial
vaccine. The animals immunized with rRVGP also survived the rabies virus challenge, whereas two negative group controls did not.
This bioprocess enables an efficient scale-up of the production with high quality immunoactive glycoprotein and may be promising
in terms of obtaining rRVGP in the near future in the order of grams for use in immunological, preclinical or clinical assessments.
Biography
Monize C Decarli is Biotechnologist. She has completed her Bachelor’s and Master’s degrees at Federal University of São Carlos, UFSCar, SP, Brazil and currently, she is
developing her PhD Thesis in Chemical Engineering at the State University of Campinas (UNICAMP, SP, Brazil). She has expertise in Bioprocess, Biotechnology, Animal
Cell Culture and Microbiology, and has been working in these fields since 2010. She has developed the bioprocess production of rRVGP in Wave Bioreactor for two years
and half, in the course of her Master research work. This approach can be promising in terms of obtaining in the near future rRVGP in order of grams to use in preclinical
assessments aiming the development of a recombinant rabies vaccine.
Monize C Decarli et al., J Biotechnol Biomater 2017, 7:6 (Suppl)
DOI: 10.4172/2155-952X-C1-085